Exploring the therapeutic potential and in vitro validation of baicalin for the treatment of triple-negative breast cancer
Baicalin inhibits the protein expression of MMP9, TNF-α and JAK2 and their related signaling pathways in the treatment of triple-negative breast cancer.
Authors
- Hai‐Tao He (ORCID: https://orcid.org/0000-0002-6594-290X)
- Qiancheng Zhao (ORCID: https://orcid.org/0000-0003-3751-4235)
- Lingxiao Pan (ORCID: https://orcid.org/0000-0001-6799-1855)
- Yuan Ma (ORCID: https://orcid.org/0009-0002-5040-0339)
- Wenfeng Zhang (ORCID: https://orcid.org/0000-0002-6113-0285)
- Yiming Yang (ORCID: https://orcid.org/0000-0003-0133-3387)
- Ying Pan (ORCID: https://orcid.org/0000-0001-8606-9815)
- Chongheng Zhang (ORCID: https://orcid.org/0000-0003-2991-030X)
- Jianling Jia
- A. SHI (ORCID: https://orcid.org/0009-0009-7663-6527)
Institutions
- Jilin University (CN)
- First Hospital of Jilin University (CN)
- Changchun University of Chinese Medicine (CN)
- Jilin Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fphar.2025.1530056
- Citations
- 6
- Primary Topic
- Flavonoids in Medical Research
- Type
- article
- Field-Weighted Citation Impact
- 8.37
Funders
- National Natural Science Foundation of China
- People's Government of Jilin Province
- Jilin University
- Education Department of Jilin Province